Oramed Pharmaceuticals Inc. (ORMP.TA)
- Previous Close
803.40 - Open
803.40 - Bid 795.00 x --
- Ask 805.30 x --
- Day's Range
797.00 - 817.00 - 52 Week Range
700.70 - 1,000.00 - Volume
8,641 - Avg. Volume
15,926 - Market Cap (intraday)
328.969M - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.73 - Earnings Date May 13, 2025 - May 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
www.oramed.comRecent News: ORMP.TA
View MorePerformance Overview: ORMP.TA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORMP.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORMP.TA
View MoreValuation Measures
Market Cap
327.56M
Enterprise Value
-183.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.25%
Return on Equity (ttm)
-12.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.06M
Diluted EPS (ttm)
-1.73
Balance Sheet and Cash Flow
Total Cash (mrq)
141.93M
Total Debt/Equity (mrq)
0.26%
Levered Free Cash Flow (ttm)
-1.51M